Whether your work focuses on research, translational studies, clinical insights, or patient experience, we want to hear from you.
📧 Send your posters to gmcancer.academy@nhs.net by 12 January 2026 (COP)
Whether your work focuses on research, translational studies, clinical insights, or patient experience, we want to hear from you.
📧 Send your posters to gmcancer.academy@nhs.net by 12 January 2026 (COP)
If you're a University of Manchester, Leeds or St Andrews medical student looking to combine your clinical training with a research PhD, check out our new MB-PhD projects.
📅 9 March 2026
🔗https://crukcentre.manchester.ac.uk/opportunity_category/mb-phd/
Working with @oncocook.bsky.social @aliciamconway.bsky.social and others at the CRUK National Biomarker Centre and The Christie Hospital. Understanding malignancy of unknown origin (MUO). Info below 👇🏻
‘Malignancy of unknown origin: Solving the origin to improve treatments and outcomes’
📆 Deadline: 9 June
🔗https://crukcentre.manchester.ac.uk/opportunities/malignancy-of-unknown-origin-solving-the-origin-to-improve-treatments-and-outcomes/
Working with @oncocook.bsky.social @aliciamconway.bsky.social and others at the CRUK National Biomarker Centre and The Christie Hospital. Understanding malignancy of unknown origin (MUO). Info below 👇🏻
AMMF-funded work by Dr Alicia-Marie Conway is adapting the CUPiD platform—originally developed for cancers of unknown primary—to detect confirmed CCA cases. A promising step toward more accurate, non-invasive diagnosis.
@cruk-mi.bsky.social
#AMMF2025
AMMF-funded work by Dr Alicia-Marie Conway is adapting the CUPiD platform—originally developed for cancers of unknown primary—to detect confirmed CCA cases. A promising step toward more accurate, non-invasive diagnosis.
@cruk-mi.bsky.social
#AMMF2025
https://buff.ly/4fZbbDy
https://buff.ly/4fZbbDy